January 2, 2009 — On December 31, 2008, Celgene, the manufacturer of tinzaparin sodium injection (Innohep) issued a Dear Healthcare Professional Letter in regard to an increased risk for death in ...

The FDA has received information about the Innohep in Renal Insufficiency Study (IRIS) that was stopped early because of an interim finding of increased all-cause mortality in patients who received ...

December 3, 2008 — The increased risk for mortality associated with tinzaparin sodium (Innohep, Pharmion Corp) may not be limited to patients aged 90 years and older, the US Food and Drug ...

Tinzaparin (Innohep (10000 iu)) is an anticoagulant, prescribed for deep vein thrombosis with or without pulmonary embolism.It works by blocking the formation of blood clots. The information provided ...

Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep injection (tinzaparin sodium) may increase the risk for death, compared to ...

LEO Pharma, an independent, research-based pharmaceutical company announced that the study showed that innohep lowered the risk of recurrent venous thromboembolism (VTE) compared to treatment with ...